Nuclear Medicine and Molecular Imaging最新文献

Bridging the Gap in Theranostics: Where Do We Stand? 弥合治疗学的鸿沟：我们站在哪里？

IF 2.7

Nuclear Medicine and Molecular Imaging Pub Date : 2025-10-01 Epub Date: 2025-09-08 DOI: 10.1007/s13139-025-00949-7

Hee-Seung Henry Bom, Ilhan Lim

引用次数: 0

Bridging the Gap: PSMA Radioligand Therapy for Asian Men with Prostate Cancer. 弥合差距：PSMA放射治疗亚洲男性前列腺癌。

IF 2.7

Nuclear Medicine and Molecular Imaging Pub Date : 2025-10-01 Epub Date: 2025-08-26 DOI: 10.1007/s13139-025-00946-w

Minseok Suh, Joo Hyun O

{"title":"Bridging the Gap: PSMA Radioligand Therapy for Asian Men with Prostate Cancer.","authors":"Minseok Suh, Joo Hyun O","doi":"10.1007/s13139-025-00946-w","DOIUrl":"10.1007/s13139-025-00946-w","url":null,"abstract":"Abstract: Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is transforming the treatment landscape for prostate cancer. However, clinical data and outcomes for Asian patients remain limited and they are underrepresented in pivotal clinical trials. Although emerging retrospective series from Asia demonstrate comparable efficacy and safety profiles to Western cohorts, several points warrant attention. Asian men frequently present with aggressive, advanced-stage disease and distinct genomic profiles, characterized by lower rates of ERG fusions and TP53/PTEN mutations, and higher frequencies of FOXA1 and SPOP alterations. These genomic differences could influence PSMA expression and responsiveness to therapy. Additionally, Asian populations exhibit higher susceptibility to myelosuppression, necessitating careful patient selection and dose management. The development of region-specific radiopharmaceuticals and clinical trials, alongside systematic real-world data collection, will be essential for optimizing PSMA-targeted RLT in Asian contexts. Incorporating PSMA-based therapies earlier in disease management strategies also presents promising avenues for improving outcomes. Personalized approaches informed by ethnic-specific disease biology and clinical experience will be crucial for effectively bridging the current knowledge gaps in PSMA-targeted RLT for Asian prostate cancer patients.Clinical trial number: Not applicable.","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"59 5","pages":"342-350"},"PeriodicalIF":2.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145113545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Theranostic Application of Radiohalogens in Nuclear Medicine. 放射性卤素在核医学中的治疗应用。

IF 2.7

Nuclear Medicine and Molecular Imaging Pub Date : 2025-10-01 Epub Date: 2025-08-16 DOI: 10.1007/s13139-025-00937-x

Choong Mo Kang

引用次数: 0

Exploring the Diagnostic and Theranostic Role of FAPI PET in Soft Tissue Sarcoma: A Systematic Review. 探讨FAPI PET在软组织肉瘤诊断和治疗中的作用：系统综述。

IF 2.7

Nuclear Medicine and Molecular Imaging Pub Date : 2025-10-01 Epub Date: 2025-08-16 DOI: 10.1007/s13139-025-00936-y

Marwah Abdulrahman, Frederik Giesel, Andrew M Scott, Hongcheng Shi, Habib Zaidi, Ahmed Saad Abdlkadir, Sameer Yaser, Ramiz Abuhijlih, Akram Al-Ibraheem

{"title":"Exploring the Diagnostic and Theranostic Role of FAPI PET in Soft Tissue Sarcoma: A Systematic Review.","authors":"Marwah Abdulrahman, Frederik Giesel, Andrew M Scott, Hongcheng Shi, Habib Zaidi, Ahmed Saad Abdlkadir, Sameer Yaser, Ramiz Abuhijlih, Akram Al-Ibraheem","doi":"10.1007/s13139-025-00936-y","DOIUrl":"https://doi.org/10.1007/s13139-025-00936-y","url":null,"abstract":"This systematic review evaluates the diagnostic and theranostic utilities of fibroblast activation protein inhibitor (FAPI PET) in patients with soft tissue sarcomas (STS). PubMed, Scopus, and Web of Science were researched for clinical studies employing FAPI PET in STS, covering literature up to October 15, 2024. This review synthesized 36 studies, involving 316 patients and about 30 STS subtypes. Twenty-one case reports highlighted FAPI's diagnostic utility. Comparative analyses often favored FAPI PET/CT over FDG PET/CT for tumor delineation, showing higher SUVmax and tumor-to-background ratios, especially in vascular tumors. Seven original studies consistently reported reliable FAPI uptake metrics across STS subtypes in 253 patients, strongly correlating with FAP immunohistochemistry. FAPI PET/CT generally demonstrated higher uptake, improved accuracy, and better lesion detection than FDG PET/CT, supporting its use in staging and restaging of recurrent and metastatic STS. Eight studies assessed FAPI PET/CT for FAPI-based radioligand therapy (RLT) eligibility, with posttherapeutic outcome predominantly resulted in disease stabilization (16 out of 36 patients), and a favorable safety profile. FAPI PET/CT outperforms FDG in detecting recurrent/metastatic STS, offering higher accuracy in most STS types. FAPI-based radioligand therapy is a promising, safe treatment for challenging STS, with encouraging efficacy.Supplementary information: The online version contains supplementary material available at 10.1007/s13139-025-00936-y.","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"59 5","pages":"289-305"},"PeriodicalIF":2.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145113641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Theranostics in the Indian Subcontinent: Opportunities, Challenges, and the Path Forward. 印度次大陆的治疗学：机遇、挑战和前进的道路。

IF 2.7

Nuclear Medicine and Molecular Imaging Pub Date : 2025-10-01 Epub Date: 2025-06-14 DOI: 10.1007/s13139-025-00931-3

Punit Sharma

引用次数: 0

Real Challenges Before, During, and after Establishing a Theranostics Center in Developing Countries. 在发展中国家建立治疗学中心之前、期间和之后的真正挑战。

IF 2.7

Nuclear Medicine and Molecular Imaging Pub Date : 2025-10-01 Epub Date: 2025-04-15 DOI: 10.1007/s13139-025-00918-0

Patricia Bautista-Peñalosa

{"title":"Real Challenges Before, During, and after Establishing a Theranostics Center in Developing Countries.","authors":"Patricia Bautista-Peñalosa","doi":"10.1007/s13139-025-00918-0","DOIUrl":"https://doi.org/10.1007/s13139-025-00918-0","url":null,"abstract":"Theranostics, the combined use of radiopharmaceuticals for diagnosis and therapy, has seen a significant evolution, accelerated by its application in prostate cancer. While this field has grown exponentially over the past decade, its implementation remains fraught with challenges, especially in developing countries. These challenges span three stages: pre-establishment, establishment, and post-establishment of theranostics centers. This article explores these obstacles and offers insights into overcoming them. In the pre-establishment phase, key barriers include limited government funding, lack of administrative support, and personal risks. During establishment, multitasking, the absence of trained personnel, and resource shortages are prominent hurdles. Post-establishment trials include overcoming colonial mentality, limited patient access due to financial constraints, logistical difficulties, and a lack of research capacity, among others. Despite these tests, successful establishment of theranostics centers is possible through strong leadership, rigorous training, international collaboration, and a patient-centered approach. The experience of the Philippines illustrates that, while the road is challenging, it is ultimately achievable with clear vision, unrelenting dedication, and the stakeholders' cooperation.","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"59 5","pages":"371-375"},"PeriodicalIF":2.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145113669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fibroblast Activation Protein-Targeted Theranostics: Current Status in Clinical Development. 成纤维细胞活化蛋白靶向治疗：临床发展现状。

IF 2.7

Nuclear Medicine and Molecular Imaging Pub Date : 2025-10-01 Epub Date: 2025-08-11 DOI: 10.1007/s13139-025-00935-z

Yeon-Koo Kang

{"title":"Fibroblast Activation Protein-Targeted Theranostics: Current Status in Clinical Development.","authors":"Yeon-Koo Kang","doi":"10.1007/s13139-025-00935-z","DOIUrl":"https://doi.org/10.1007/s13139-025-00935-z","url":null,"abstract":"Fibroblast activation protein (FAP) has attracted growing interest as a promising target for cancer imaging and therapy due to its highly selective expression in the tumor stroma. This review summarizes the current development status of FAP-targeted radioligand therapy based on clinical evidence reported to date. Early therapeutic pipelines utilized quinoline-based compounds such as FAPI-04 and FAPI-46, predominantly investigated for PET imaging, by labeling them with beta-emitting radionuclides. Despite high tumor uptake, these early agents showed limited therapeutic efficacy due to short tumor retention and insufficient intratumoral radiation dose. To overcome this limitation, various structural modifications have been investigated to improve tumor retention, including cyclic peptides, dimers, and albumin binders. Several of these modified agents have been evaluated in clinical studies, showing improved tumor dosimetry while maintaining acceptable normal organ doses and toxicity profiles. However, therapeutic outcomes remain inconclusive, and evidence from large-scale, well-structured studies is still lacking. Currently, a few compounds are under investigation in early-phase clinical trials aimed at regulatory approval for clinical use. Evidence of therapeutic efficacy from those strictly designed clinical trials is awaited.","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"59 5","pages":"279-288"},"PeriodicalIF":2.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145113696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Artificial Intelligence in Advancing Theranostics Dosimetry for Cancer Therapy: a Review. 人工智能在推进癌症治疗放射学剂量学中的作用综述。

IF 2.7

Nuclear Medicine and Molecular Imaging Pub Date : 2025-10-01 Epub Date: 2025-08-23 DOI: 10.1007/s13139-025-00939-9

Sang-Keun Woo

{"title":"The Role of Artificial Intelligence in Advancing Theranostics Dosimetry for Cancer Therapy: a Review.","authors":"Sang-Keun Woo","doi":"10.1007/s13139-025-00939-9","DOIUrl":"10.1007/s13139-025-00939-9","url":null,"abstract":"Cancer treatment has greatly benefited from advancements in radiopharmaceutical therapy, which requires precise dosimetry to enhance therapeutic efficacy and minimize risks to healthy tissues. This review investigated the role of artificial intelligence (AI) in theranostic radiopharmaceutical dosimetry, focusing on image quality enhancement, dose estimation, and organ segmentation. An in-depth review of the literature was conducted using targeted keywords searches in Google Scholar, PubMed, and Scopus. Selected studies were evaluated for their methodologies and outcomes. Traditional dosimetry techniques such as organ-level and voxel-based methods are discussed. Deep learning (DL) models based on U-Net, generative adversarial networks, and hybrid transformer networks for image synthesis and generation, image quality improvement, organ segmentation, and radiation dose estimation are reviewed and discussed. While DL shows great potential for enhancing dosimetry accuracy and efficiency, challenges such as the need for accurate dose estimation from theranostic pairs, lack of imaging data, and modeling of radionuclide decay chains must be addressed using DL models. In addition, the optimization and standardization of DL and AI models is crucial for ensuring clinical reliability and should be given high priority to support their effective integration into clinical practice.","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"59 5","pages":"329-341"},"PeriodicalIF":2.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145113729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current Status of Theranostics in West Asia: A Country-based Surveillance Study. 西亚治疗学现状：一项基于国家的监测研究。

IF 2.7

Nuclear Medicine and Molecular Imaging Pub Date : 2025-10-01 Epub Date: 2025-03-20 DOI: 10.1007/s13139-025-00914-4

Akram Al-Ibraheem, Ahmed Saad Abdlkadir, Batool Albalooshi, Maryam Alkuwari, Dyab Al Mahariq, Khalsa Al-Nabhani, Abdullah Alqarni, Mohammed Al-Rowaily, Riyadh AlSalloum, Murat Fani Bozkurt, Habibollah Dadgar, Abdulredha Esmail, Shazia Fatima, Mohamad Haidar, Aysar Khalaf, Fairoz Mohammed, Fuad Novruzov, Majdi Zein

{"title":"Current Status of Theranostics in West Asia: A Country-based Surveillance Study.","authors":"Akram Al-Ibraheem, Ahmed Saad Abdlkadir, Batool Albalooshi, Maryam Alkuwari, Dyab Al Mahariq, Khalsa Al-Nabhani, Abdullah Alqarni, Mohammed Al-Rowaily, Riyadh AlSalloum, Murat Fani Bozkurt, Habibollah Dadgar, Abdulredha Esmail, Shazia Fatima, Mohamad Haidar, Aysar Khalaf, Fairoz Mohammed, Fuad Novruzov, Majdi Zein","doi":"10.1007/s13139-025-00914-4","DOIUrl":"https://doi.org/10.1007/s13139-025-00914-4","url":null,"abstract":"This surveillance study examined the status of theranostics in West Asia, analyzing data from 15 countries. The research assessed availability, production, coverage, staff density, infrastructure density, financial and political impacts. All surveyed countries except Yemen offered theranostic services, with 452 centers and 1,426 theranostic physicians across the region. Over half of the countries reported densities exceeding one theranostician, nuclear medicine technologist, physicist, and nurse per million inhabitants. Scientific and social activities were available in nine and ten countries, respectively. Countries with gross domestic product (GDP) below $200 billion showed significantly lower infrastructure and manpower resources, particularly in cyclotron availability and theranostic agents (p < 0.05), compared to those with higher GDP. Politically stable countries demonstrated statistically higher densities of theranostic personnel than unstable nations (p < 0.05). The study emphasizes the importance of collaboration between model countries and those lacking adequate services to enhance theranostic practice and availability in West Asia.","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"59 5","pages":"351-359"},"PeriodicalIF":2.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446171/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145113605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances and Challenges in the Application of Radiolabeled Magnetic Nanoparticles for Cancer Theranostics. 放射性磁性纳米颗粒在癌症治疗中的应用进展与挑战。

IF 2.7

Nuclear Medicine and Molecular Imaging Pub Date : 2025-10-01 Epub Date: 2025-08-26 DOI: 10.1007/s13139-025-00943-z

Zahra Shaghaghi, Sahar Nosrati, Ramin Mansouri, Maryam Alvandi

{"title":"Advances and Challenges in the Application of Radiolabeled Magnetic Nanoparticles for Cancer Theranostics.","authors":"Zahra Shaghaghi, Sahar Nosrati, Ramin Mansouri, Maryam Alvandi","doi":"10.1007/s13139-025-00943-z","DOIUrl":"https://doi.org/10.1007/s13139-025-00943-z","url":null,"abstract":"Radiolabeled magnetic nanoparticles (MNPs), particularly superparamagnetic iron oxide nanoparticles (SPIONs), have gained significant attention in the field of cancer theranostics due to their potential in targeted therapy and molecular imaging. This review highlights recent advancements in the development of various radiolabeled SPIONs, including those functionalized with polyethylene glycol (PEG), DTPA, and other targeting agents. These nanoparticles are designed for multiple clinical applications, including hyperthermia, magnetic resonance imaging (MRI), and radiotherapy. However, the translation of these promising nanostructures into clinical practice faces several challenges, such as issues with surface functionalization, toxicity, stability, and the complexities of multimodal imaging. The review also explores creative approaches to overcome these challenges, such as designing multicomponent nanostructures, utilizing chelator-based and chelator-free radiolabeling techniques, employing click chemistry for radiolabeling, and enhancing biocompatibility methods. Ultimately, radiolabeled SPIONs have the potential to revolutionize cancer treatment and imaging, but further optimization is required to overcome existing obstacles and enhance their clinical applicability.","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"59 5","pages":"315-328"},"PeriodicalIF":2.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446173/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145113464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0